Articles related to PTSD

Short-term benzodiazepine use after mass trauma was not associated with increased 12-month PTSD risk in a large retrospective cohort. Persistent use showed a different pattern, and the observational findings did not establish causality.

An EEG-guided neuromodulation system received FDA clearance for PTSD treatment based on a randomized controlled trial. The platform uses individualized brain activity data to guide therapy, though detailed efficacy results have not been disclosed.

FDA priority review vouchers granted to three psychedelic developers and a recent executive order may accelerate regulatory timelines for psilocybin and related compounds, with clinical availability potentially within 12 months pending positive Phase 3 data.

The recall encompasses three dosages for prazosin hydrochloride capsules: 181K+ bottles of 1-milligram doses, 291K+ bottles of 2-milligram doses, and 107K+ bottles of 5-milligram doses, all distributed nationwide.

For physicians, especially residents, the exposure to work-related trauma is not only prevalent but carries a significant risk of PTSD, a condition marked by a broad spectrum of physical and psychological symptoms.

A recent JAMA Network Open study reveals Trauma Center Trauma-Sensitive Yoga as a highly acceptable and effective treatment for PTSD in women veterans, exhibiting a higher completion rate than Cognitive Processing Therapy.